Pharma Bio Services (PBSV) AI Stock Analysis

• Market Cap: $13.76M
• Dividend Yield: N/A
• Average Volume (3M): 6.71K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.14
• Revenue Growth: -25.46%
• EPS Growth: -4000.00%
• Country: US
• Employees: 75
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Healthcare Information Services
• EPS (TTM): <0.01
• Shares Outstanding: 22,927,942
• 10 Day Avg. Volume: 7,113
• 30 Day Avg. Volume: 6,710
• PEG Ratio: -13.82
• Price to Book (P/B): 1.14
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.26
• Enterprise Value/Market Cap: 0.86
• Enterprise Value/Revenue: 0.30
• Enterprise Value/Gross Profit: 3.99
• Enterprise Value/Ebitda: -3.39
• 1Y Price Target: $0.50
• Price Target Upside: -16.67% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 50 Neutral
• Price Target: $0.50 ▼(-16.67%Downside)

Pharma Bio Services' overall stock score is impacted primarily by its financial performance challenges, particularly in revenue and cash flow. Technical analysis provides some positive momentum, but valuation concerns with a negative P/E ratio weigh heavily on the score. The lack of earnings call data and corporate events means these factors do not influence the score.

Pharma Bio Services Business Overview & Revenue Model

Company Description

Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm. The company provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products companies in Puerto Rico, the United States, Europe, and Brazil. Its technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico.

How the Company Makes Money

Pharma Bio Services makes money primarily through consultancy fees charged for their expert services. Their revenue streams include regulatory compliance consulting, where they help pharmaceutical companies navigate complex regulatory environments to bring products to market successfully. Additionally, PBSV earns from quality assurance services, ensuring products meet necessary safety and efficacy standards, and from clinical research services, where they support the design and execution of clinical trials. Significant partnerships with pharmaceutical companies and biotechnology firms, as well as long-term contracts, contribute to their stable earnings.

Pharma Bio Services Financial Statement Overview

Summary

Pharma Bio Services faces significant challenges with declining revenue and profitability. The income statement shows a substantial decline in revenue and profitability, with a low net profit margin of 0.32%. The balance sheet is robust with a high equity ratio of 74.58%, indicating financial stability. However, cash flow is concerning with negative free and operating cash flows, highlighting liquidity issues.

Income Statement

The company shows a substantial decline in revenue and profitability. The TTM gross profit margin is 31.06%, indicating some efficiency in controlling production costs despite a negative EBIT and EBITDA margin. The net profit margin is low at 0.32%, reflecting weak profitability. Revenue growth is negative, suggesting challenges in maintaining sales levels.

Balance Sheet

Pharma Bio Services has a strong equity position with a high equity ratio of 74.58%, reflecting financial stability and low leverage. However, the debt-to-equity ratio is 0.01, indicating a low level of leverage which reduces financial risk. The company’s high stockholders' equity is a positive factor in its financial health.

Cash Flow

The cash flow statement reveals negative free cash flow and operating cash flow, indicating liquidity concerns. The operating cash flow to net income ratio is negative, highlighting inefficiencies in converting income into cash flows. Free cash flow shows no growth, suggesting potential cash management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.64M	9.51M	16.98M	19.40M	20.12M	21.56M
Gross Profit	2.95M	2.52M	5.07M	4.88M	5.36M	6.67M
EBITDA	-523.87K	-574.28K	1.31M	1.23M	-3.78M	2.31M
Net Income	-189.19K	-777.62K	1.31M	1.01M	-2.09M	2.05M
Balance Sheet
Total Assets	13.90M	16.29M	19.90M	20.65M	23.92M	29.92M
Cash, Cash Equivalents and Short-Term Investments	10.41M	12.75M	14.98M	14.46M	17.47M	17.14M
Total Debt	113.04K	194.03K	346.51K	487.36K	617.42K	2.79M
Total Liabilities	1.78M	2.58M	3.78M	4.09M	5.01M	7.20M
Stockholders Equity	12.12M	13.72B	16.13M	16.56M	18.91M	22.72M
Cash Flow
Free Cash Flow	-1.49M	-726.44K	1.88M	573.19K	794.00K	1.47M
Operating Cash Flow	-1.32M	-566.70K	1.89M	592.46K	804.84K	1.53M
Investing Cash Flow	1.62M	-1.36M	-4.22M	-19.27K	1.30M	-28.96K
Financing Cash Flow	-1.74M	-1.73M	-1.76M	-3.53M	-1.75M	193.68K

Pharma Bio Services Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBSV, the sentiment is Positive. The current price of 0.6 is above the 20-day moving average (MA) of 0.55, above the 50-day MA of 0.50, and above the 200-day MA of 0.49, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 60.05 is Neutral, neither overbought nor oversold. The STOCH value of 92.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBSV.

Pharma Bio Services Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.51B	0.24	-62.67%	2.30%	16.09%	0.95%
STRM	51 Neutral	$22.87M	―	-63.93%	―	-14.88%	54.76%
PBSV	50 Neutral	$13.76M	―	-1.45%	―	-25.46%	-4000.00%
SCNX	39 Underperform	$20.86M	―	-30.97%	―	-97.79%	86.73%
ONMD		$19.22M	―		―	―	―
HCTI	27 Underperform	$9.19M	―	-143.99%	―	-64.77%	43.53%
BFRG		$14.22M	―	-141.43%	―	―	―

Pharma Bio Services Corporate Events

Pharma Bio Services Elects New Director at Annual Meeting

On May 15, 2025, Pharma-Bio Serv, Inc. held its 2025 Annual Meeting of Stockholders where Howard Spindel was elected as a Class III director until the 2028 Annual Meeting. The selection of Crowe PR PSC as the Company’s independent certified public accountants for the fiscal year ending October 31, 2025, was ratified. Additionally, a non-binding advisory vote determined that the compensation of the named executive officers will be reviewed every three years.